

AD \_\_\_\_\_

Award Number: DAMD17-03-1-0761

TITLE: Annexin II - Mediated Ca++ Influx Regulates Endothelial  
Cell (EC) Apoptosis and Tumor Angiogenesis

PRINCIPAL INVESTIGATOR: Mahesh C. Sharma, Ph.D.

CONTRACTING ORGANIZATION: Drexel University  
Philadelphia, Pennsylvania 19104

REPORT DATE: October 2004

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20050415 083

**REPORT DOCUMENTATION PAGE**Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

<b>1. AGENCY USE ONLY</b> (Leave blank)		<b>2. REPORT DATE</b> October 2004	<b>3. REPORT TYPE AND DATES COVERED</b> Annual (15 Sep 2003 - 14 Sep 2004)	
<b>4. TITLE AND SUBTITLE</b> Annexin II - Mediated Ca++ Influx Regulates Endothelial Cell (EC) Apoptosis and Tumor Angiogenesis			<b>5. FUNDING NUMBERS</b> DAMD17-03-1-0761	
<b>6. AUTHOR(S)</b> Mahesh C. Sharma, Ph.D.				
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> Drexel University Philadelphia, Pennsylvania 19104  E-Mail: Ms66@drexel.edu			<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			<b>10. SPONSORING / MONITORING AGENCY REPORT NUMBER</b>	
<b>11. SUPPLEMENTARY NOTES</b>				
<b>12a. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for Public Release; Distribution Unlimited			<b>12b. DISTRIBUTION CODE</b>	
<b>13. ABSTRACT (Maximum 200 Words)</b> <p>Angiostatin (AS), the first four kringle domain (K1-4) of plasminogen (PLG), blocks angiogenesis and breast cancer progression almost 95 % in xenograft model. Despite great therapeutic potential in breast cancer its mechanism of action is unclear. We previously reported that AS ligand binds to endothelial cell surface annexin II and blocks PLG bindings. Emerging role of annexin II in cancer prompted us to investigate its possible mechanism in breast cancer. In this study we report that that annexin II gene and protein abundantly expressed in highly invasive and metastatic breast cancer cells MDA-MB231 but not in non invasive MCF-7 cells. Annexin II expression is regulated by proangiogenic growth factors. Growth factors also phosphorylate tyrosine residue of annexin II in MDA-MB231 cells indicating the involvement of signal transduction mechanism. MDA-MB231 cells activated PLG to plasmin (PL) in time dependent manner whereas MCF-7 cells lacking annexin II expression failed to activate PLG indicating that MDA-MB231 cells require annexin II for PLG activation and may be involved in invasion and migration. Our data indicates that MDA-MB231 cells induced invasion through ECM in PLG dependent manner but MCF-7 failed to invade and migrate suggesting specific role of annexin II mediated PL generation in invasion and migration. It is possible to block breast cancer invasion and migration by blocking annexin II and may be an attractive target.</p>				
<b>14. SUBJECT TERMS</b> Annexin II, angiogenesis, breast cancer, invasion			<b>15. NUMBER OF PAGES</b> 12	
			<b>16. PRICE CODE</b>	
<b>17. SECURITY CLASSIFICATION OF REPORT</b> Unclassified	<b>18. SECURITY CLASSIFICATION OF THIS PAGE</b> Unclassified	<b>19. SECURITY CLASSIFICATION OF ABSTRACT</b> Unclassified	<b>20. LIMITATION OF ABSTRACT</b> Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)  
Prescribed by ANSI Std. Z39-18  
298-102

## Table of Contents

Cover.....	1
SF 298.....	2
Introduction.....	3
Body.....	5
Key Research Accomplishments.....	8
Reportable Outcomes.....	8
Conclusions.....	9
References.....	9
Appendices.....	

**Introduction:** It has been recognized for decades that growth and development of breast cancer is dependent on angiogenesis [1]. Weidener *et al* reported that microvessel density (either count or grade serves as a measure of tumor angiogenesis) in invasive breast carcinoma is associated with metastasis and, thus, may be a prognostic indicator [2, 3]. Increase in tumor microvasculature not only allows for rapid growth of tumors but may also provide the means for tumor cells to enter and exit the circulation during hematogenous tumor spread. In addition, endothelial cells (EC) may play a significant role in tumor progression by providing invading tumor cells with essential molecules necessary for extracellular matrix (ECM) degradation such as proteolytic enzymes [4]. Therefore, tumor angiogenesis plays an active and critical role in tumor progression and metastasis.

Regulation of angiogenesis is a fundamental mechanism to control of tumor progression [1]. Using this novel approach, Folkman and colleagues identified angiostatin (AS), an internal fragment of plasminogen (PLG) spanning kringle 1-4 region, as one of the most powerful angiogenesis inhibitors [5]. These investigators further demonstrated 95% regression of human breast cancer by AS treatment in xenograft mice model without toxicity [6]. Later other investigators also demonstrated impressive anti-human breast cancer activity by AS gene therapy [7]. Recently, AS therapy has been reported to inhibit breast cancer induced bone metastasis [8]. Angiostatin was the first anti-angiogenic protein to enter therapeutic cancer clinical trials.

Despite the potential anti-breast cancer therapeutic value of AS, its clinical utility is hampered by limited availability of the recombinant bioactive AS. Human pharmacokinetics, particularly a short half-life in circulation [6] makes drug delivery challenging. Since discovery of AS, various mechanism(s) of action for AS have been suggested, including from our laboratory. Despite the identification of multiple receptors for AS [9-11], current knowledge of how AS inhibits breast cancer growth and metastasis is still unclear. If mechanism of action for AS is identified, more candidate drugs can be developed to target receptor(s).

To delineate the AS's molecular mechanism we identified, purified and characterized a potential receptor for AS from EC surface [12, 13]. Using proteomics approach we have identified this protein as annexin II [12] and proposed a likely mechanism in angiogenesis. To explore its mechanism in breast cancer we have identified expression of AS's receptor annexin II in invasive human breast cancer cell line (MDA-MB231) in vitro and human ductal carcinoma in vivo [14]. Annexin II is one of the most abundant EC surface fibrinolytic receptors for PLG [15]. It is capable of converting inactive enzyme PLG to highly active protease plasmin (PL) almost 300 fold [16]. Consistent with previous observations we found that invasive MDA-MB231 cells expressing high levels of annexin II were also capable of converting PLG to PL with high efficiency. This is in contrast to poorly invasive cell line (MCF-7), which failed to convert PLG to PL (see preliminary data). Pericellular plasmin-mediated degradation of extracellular matrix (ECM) has been reported to induce tumor cell invasion, metastasis and tumor progression [17-19]. In addition, plasmin liberates matrix bound pro growth factors bFGF and VEGF during proteolysis of ECM [20]. Furthermore, plasmin mediated proteolytic processing of growth factors is required to induce cell proliferation and tumor progression [21]. Thus, annexin II may play a pivotal role in the **pro-anti-angiogenic switch mechanism** through precise regulation of PLG and growth factors activation. Recent studies on PLG knockout mice (PLG<sup>-/-</sup>) reported an absolute requirement for plasmin in cancer invasion, angiogenesis and tumor progression [22-24]. This suggests that invasive breast cancer cells generate plasmin with a prominent role in ECM degradation, invasion for tumor progression and metastasis to distant sites. In this context, plasmin inhibitors have been tested in clinical setting as well as in xenograft mouse model of

cancer and showed promising results [25-27]. In our laboratory we have made a direct attempt to block in vivo annexin II mediated plasmin generation in mouse model of Lewis Lung Carcinoma (LLC) and found remarkable inhibition of tumor growth by monoclonal antibody mediated blocking of annexin II [28] (see appendix).

Bone is very common metastatic site for breast cancer. Emerging studies suggest that AS treatment inhibits MDA-MB231 induced bone metastasis through direct anti-osteoclastic activity [8]. It is interesting to note that annexin II increases osteoclast formation and bone resorption [29, 30]. These reports further support the link between annexin II and breast cancer metastasis and also strongly support our findings. It is likely that AS inhibiting breast cancer progression and metastasis by blocking annexin II functions in invasive breast cancer as we propose. Targeting this component of fibrinolytic system (PLG/PL) has yielded exciting results in the war against cancer [31, 32]. It remains to be seen whether targeting fibrinolytic receptor annexin II will have clinical efficacy yet to be answered.

Another central function of annexin II in the cell is its role in signal transduction mechanism. Annexin II is a calcium and phospholipid binding protein and major in vivo substrate for protein tyrosine kinase and PKC [33, 34]. It binds to the cytoskeleton protein actin and helps to organize into dynamic meshwork of actin fibers. Recent reports suggest that AS treatment induces the rise in intracellular calcium ( $[Ca^{++}]_i$ ) through the PI-3 kinase signaling pathways [35], which requires reorganization of the actin cytoskeleton. Reports suggest that contact between breast cancer cells and EC induces an immediate and transient increase in intracellular  $[Ca^{2+}]$  [36] indicating that signal transduction pathways are involved in these interactions. It is conceivable that targeted disruption of annexin II by AS treatment may disorganize actin microfilament architecture, affecting cellular physiology such as cell-cell interaction, migration and proliferation [37]. Targeted disruption of actin microfilament assembly has been demonstrated in invasive (MDA-MB231) breast cancer cell death and morphological changes in cell shape [38]. Annexin II has a limited tissue distribution and is not typically expressed in normal and mature organs such as liver and brain (Sharma et al, unpublished observations). However, its expression in liver cancer and brain tumor are highly up regulated [28, 39-41]. We found that quiescent EC do not express annexin II but exposure to growth factors up-regulates annexin II expression suggesting its possible role in cell proliferation, angiogenesis and tumor progression. Recently we reported that anti-annexin II antibody perturbs cell growth and induces EC cell apoptosis in a dose dependent manner; disrupting blood vessel formation in vitro [42]. These data suggest that disruption of the cell surface exposed annexin II may play a pivotal role in signal transduction mechanism.

One of the attributes that metastatic cells must develop is the ability to degrade the ECM in order to initiate tumor progression and induce metastatic spread. To accomplish this, metastatic cells may activate annexin II fibrinolytic activity to generate plasmin, which in turn cleaves basement membrane constituents to clear the path for cellular invasion and migration. This is one of the prerequisite steps of angiogenic and metastatic processes. It is likely that AS binding to annexin II acts as antagonist and may disable the plasmin generation capacity of the cell and potentially inhibits invasion [22] cell migration [43] and proliferation [44, 45].

Our novel studies in breast cancer indicate that annexin II mediated plasmin provides a model system with which to further probe the molecular mechanism underlying breast tumor progression. Annexin II protein expression appears to act as a tumor and metastasis promoter by cell surface mediated plasmin generation. Our preliminary data suggest that invasive breast cancer cells are equipped with the machinery necessary for degradation of ECM initiating

angiogenesis and metastasis. It is not unreasonable to mention that AS mediated remarkable inhibition of breast cancer and metastasis [8] seen by Folkman and colleagues [6] may be due to blocking annexin II and its mediated signaling. Results obtained from this study will establish the role of fibrinolytic receptor annexin II in angiogenesis, metastasis and breast tumor progression and may lead to design of effective breast cancer therapeutics.

**Body:** We have successfully completed the task 1 as described in statement of work. We had some technical difficulty to perform the task 2. Now we have identified and solved the technical problems of the experiments in task 2. We are granted no cost extension for one year to complete the experiments described in task 2. The results of task 1 are summarized below.


**Task 1: growth factors-mediated tyrosine phosphorylation and temporal expression of annexin II in EC, MCF-7 and MDA-MB231 cells.**

- a) Effect of angiogenic growth factors on annexin II expression.
- b) Determine the growth factors stimulated tyrosine phosphorylation in EC, MCF-7 and MDA-MB231 cells.

**Results:**

**Annexin II expression in invasive and non-invasive breast cancer cells and its regulation by growth factors.** Our experimental data suggest that annexin II is specifically expressed in invasive breast cancer cells but not in hormone receptor positive non invasive breast cancer cells MCF-7.


Fig.1



**Temporal regulation of annexin II expression in invasive and non-invasive breast cancer cells by angiogenic growth factors VEGF and bFGF:**


Invasive (MDA-MB231) and noninvasive breast cancer (MCF-7) cells were cultured in presence of bFGF and VEGF for various time points. Cells were lysed and 10 µg protein was analyzed for annexin II expression by Western blot. Lane C Control (no treatment); Lanes 2,3,4 treated for 6 ,4 and 2 hours respectively. Lanes 5,6,7 were treated for 6 ,4 and 2 hours respectively. Lanes 9,10 and 11 were treated for 6 ,4 and 2 hours respectively and 12,13 and 14 were for 6 ,4 and 2 hours respectively.

**Annexin II expression is up regulated by bFGF after 2 hours in invasive breast cancer cells MDA-MB231.** Our results indicate that bFGF up regulates annexin II expression in MDA-MB231 cells within 2 hours of treatment.



**Over expression of annexin II by bFGF:** bFGF was incubated in serum free medium for 2 hours. Cell lysates were analyzed for annexin II expression. Lane #1 control; lane # 2 treated with bFGF


**Angiogenic cytokines induce annexin II expression in bovine aortic endothelial cells (BAEC).** Our experimental evidence indicates that annexin II expression is up regulated by angiogenic cytokines bFGF and VEGF suggesting its possible role in angiogenesis.



**Growth factors induce annexin II expression in endothelial cells:** Both bFGF and VEGF were incubated in serum free cultured medium for 2 hours. Cell lysates were prepared and 10- $\mu$ g protein was analyzed for annexin II expression


**Effect of growth factors on tyrosine phosphorylation of proteins in MCF-7 and MDA-MB231 cells:** Cells were stimulated by growth factors for various times to analyze the tyrosine phosphorylation of proteins. Cell lysates were separated by SDS-PAGE, transferred on to membrane and probed with anti-Tyr-P monoclonal antibody. Data presented in figure 4 indicates that both growth factors (bFGF and VEGF) induce extensive and distinct tyrosine phosphorylation of proteins in MCF-7 and MDA-MB231 cells. Importantly, we have observed specific tyrosine phosphorylation of 36-kDa protein in MDA-MB231 cells but not in MCF-7 cells. This protein showed same electrophoretic mobility as annexin II. Immunoprecipitation analysis confirmed that 36-kDa phosphoprotein is annexin II (Fig.4 B).

Fig.4 A




**bFGF induces tyrosine phosphorylation of annexin II specifically in invasive breast cancer MDA-MB231 cells:** Cells were stimulated by bFGF for 2 hours in serum free medium. After the treatment cells were lysed and immunoprecipitated by anti-Tyr-p monoclonal antibody and probed with anti-annexin II antibody.

Fig.4 B





**Effect of growth factors on tyrosine phosphorylation of proteins in BAEC:** In contrast to breast cancer cells we have observed time dependent phosphorylation of 64kDa protein in BAEC. We did not observe the phosphorylation of annexin II in BAEC.



**Effect of growth factors on tyrosine phosphorylation in EC:**  
 Bovine aortic endothelial cells (BAEC) were stimulated with growth factors for various time points as indicated in figure. Phosphotyrosine reactive proteins were identified using monoclonal antibodies Tyr-P.

#### Key Achievements:

1. Calcium binding protein annexin II specifically express in invasive breast cancer cells (MDA-MB231) but not in hormone receptor positive non-invasive breast cancer cells (MCF-7).
2. Growth factors up regulate annexin II expression in MDA-MB231 cells.
3. Annexin II acts as receptor for plasminogen on invasive MDA-MB231 cells and facilitates activation of plasminogen to plasmin. In sharp contrast, MCF-7 cells lacking annexin expression failed to activate plasmin.
4. MDA-MB231 cells were able to degrade extracellular matrix (ECM) in plasminogen dependent manner but MCF-7 cells failed to invade and migrate through ECM suggesting that annexin II mediated plasminogen activation is required for cellular invasion, migration and angiogenesis.
5. Phosphorylation of annexin II is observed only in MDA MB231 cells but not in MCF-7 cells.

**Reportable Outcomes:** Results obtained from this study will be presented in 4<sup>th</sup> Era of hope meeting in Philadelphia sponsored by the DOD. A copy of the abstract will be forwarded to your office after submission. We are also planning to write a manuscript after completing this study. The copy of the manuscript will also be forwarded.

**Conclusions:** On the basis of our experimental evidence we conclude that specific expression of annexin II on invasive breast cancer cells MDA-MB231 regulates plasminogen activation to plasmin which in turn degrades ECM and facilitates cellular invasion, migration and angiogenesis dependent tumor progression.

Angiogenic cytokines induce BAEC proliferation and correlates with annexin II expression suggesting possible role in cell proliferation and angiogenesis.

#### References:

1. Folkman, J., *Fighting cancer by attacking its blood supply*. Sci Am, 1996. 275(3): p. 150-4.
2. Weidner, N., et al., *Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma*. J Natl Cancer Inst, 1992. 84(24): p. 1875-87.
3. Weidner, N. and J. Folkman, *Tumoral vascularity as a prognostic factor in cancer*. Important Adv Oncol, 1996: p. 167-90.
4. Folkman, J., *Angiogenesis in cancer, vascular, rheumatoid and other disease*. Nat Med, 1995. 1(1): p. 27-31.
5. O'Reilly, M.S., et al., *Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma*. Cell, 1994. 79(2): p. 315-28.
6. O'Reilly, M.S., et al., *Angiostatin induces and sustains dormancy of human primary tumors in mice*. Nat Med, 1996. 2(6): p. 689-92.
7. Griscelli, F., et al., *Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest*. Proc Natl Acad Sci U S A, 1998. 95(11): p. 6367-72.
8. Peyruchaud, O., et al., *Angiostatin inhibits bone metastasis formation in nude mice through a direct anti-osteoclastic activity*. J Biol Chem, 2003. 278(46): p. 45826-32.
9. Troyanovsky, B., et al., *Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation*. J Cell Biol, 2001. 152(6): p. 1247-54.
10. Tarui, T., L.A. Miles, and Y. Takada, *Specific interaction of angiostatin with integrin  $\alpha(v)\beta(3)$  in endothelial cells*. J Biol Chem, 2001. 276(43): p. 39562-8.
11. Moser, T.L., et al., *Angiostatin binds ATP synthase on the surface of human endothelial cells*. Proc Natl Acad Sci U S A, 1999. 96(6): p. 2811-6.
12. Tuszynski, G.P., et al., *Angiostatin binds to tyrosine kinase substrate annexin II through the lysine-binding domain in endothelial cells*. Microvasc Res, 2002. 64(3): p. 448-62.
13. Sharma, M.C., M.R. Sharma, and D.H. Berger, *Identification of angiostatin binding protein in endothelial cells*. J of Surgical Research, 1999. 86(277).
14. Tuszynski, G.P., et al., *Over-expression of annexin II in invasive breast cancer cells in vitro and ductal carcinoma in vivo*. Proc. Am. Assoc. Cancer Research 43, A#129, 2002.
15. Hajjar, K.A. and J.S. Menell, *Annexin II: a novel mediator of cell surface plasmin generation*. Ann N Y Acad Sci, 1997. 811: p. 337-49.
16. Kassam, G., et al., *The p11 subunit of the annexin II tetramer plays a key role in the stimulation of t-PA-dependent plasminogen activation*. Biochemistry, 1998. 37(48): p. 16958-66.
17. blasi, F.a.S., M.P., *Proteases and cancer invasion: from belief to certainty*. Biochimica et Biophysica Acta, 1998. 1423: p. R35-R44.

18. Blei, F., et al., *Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis*. J Cell Physiol, 1993. 155(3): p. 568-78.
19. Bajou, K., et al., *The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies*. J Cell Biol, 2001. 152(4): p. 777-84.
20. Rifkin, D.B., et al., *Proteolytic control of growth factor availability*. Apmis, 1999. 107(1): p. 80-5.
21. McColl, B.K., et al., *Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D*. J Exp Med, 2003. 198(6): p. 863-8.
22. Bajou, K., et al., *[Role of plasminogen activator inhibitor type 1 in tumor angiogenesis]*. Therapie, 2001. 56(5): p. 465-72.
23. Brodsky, S., et al., *Plasmin-dependent and -independent effects of plasminogen activators and inhibitor-1 on ex vivo angiogenesis*. Am J Physiol Heart Circ Physiol, 2001. 281(4): p. H1784-92.
24. Albo, D., et al., *Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor*. Br J Cancer, 2000. 83(3): p. 298-306.
25. Szende, B., et al., *A novel plasmin-inhibitor inhibits the growth of human tumor xenografts and decreases metastasis number*. In Vivo, 2002. 16(5): p. 281-6.
26. Soma, H., et al., *Treatment of advanced ovarian cancer with fibrinolytic inhibitor (tranexamic acid)*. Acta Obstet Gynecol Scand, 1980. 59(3): p. 285-7.
27. Lentschener, C., et al., *Intraoperatively administered aprotinin increases one year survival after elective liver resection for colorectal metastasis*. Proteolysis and Fibrinolysis, 1999. 13: p. 39-45.
28. Sharma, M., et al., *Angiostatin inhibits tumor growth via the regulation of fibrinolytic system through binding its receptor annexin II*. J Clin Invest, 2004. submitted.
29. Mena, C., et al., *Annexin II increases osteoclast formation by stimulating the proliferation of osteoclast precursors in human marrow cultures*. J Clin Invest, 1999. 103(11): p. 1605-13.
30. Takahashi, S., et al., *Cloning and identification of annexin II as an autocrine/paracrine factor that increases osteoclast formation and bone resorption*. J Biol Chem, 1994. 269(46): p. 28696-701.
31. O'Reilly, M.S., et al., *Antiangiogenic activity of the cleaved conformation of the serpin antithrombin*. Science, 1999. 285(5435): p. 1926-8.
32. Rabbani, S.A. and J. Gladu, *Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo*. Cancer Res, 2002. 62(8): p. 2390-7.
33. Boyko, V., et al., *A major cellular substrate for protein kinases, annexin II, is a DNA-binding protein*. FEBS Lett, 1994. 345(2-3): p. 139-42.
34. Keutzer, J.C. and R.R. Hirschhorn, *The growth-regulated gene 1B6 is identified as the heavy chain of calpactin I*. Exp Cell Res, 1990. 188(1): p. 153-9.
35. Jiang, L., et al., *Intracellular Ca(2+) signaling in endothelial cells by the angiogenesis inhibitors endostatin and angiostatin*. Am J Physiol Cell Physiol, 2001. 280(5): p. C1140-50.

36. Lewalle, J.M., et al., *Endothelial cell intracellular Ca<sup>2+</sup> concentration is increased upon breast tumor cell contact and mediates tumor cell transendothelial migration*. Clin Exp Metastasis, 1998. 16(1): p. 21-9.
37. Hall, A., *Rho GTPases and the actin cytoskeleton*. Science, 1998. 279(5350): p. 509-14.
38. Mgbonyebi, O.P., J. Russo, and I.H. Russo, *Roscovitine induces cell death and morphological changes indicative of apoptosis in MDA-MB-231 breast cancer cells*. Cancer Res, 1999. 59(8): p. 1903-10.
39. Masaki, T., et al., *Involvement of annexin I and annexin II in hepatocyte proliferation: can annexins I and II be markers for proliferative hepatocytes?* Hepatology, 1994. 20(2): p. 425-35.
40. Roseman, B.J., et al., *Annexin II marks astrocytic brain tumors of high histologic grade*. Oncol Res, 1994. 6(12): p. 561-7.
41. Reeves, S.A., et al., *Developmental regulation of annexin II (Lipocortin 2) in human brain and expression in high grade glioma*. Cancer Res, 1992. 52(24): p. 6871-6.
42. Sharma, M.C., Meena R. Sharma, Vicki L. Rothman, George P. Tuszynski, *Targeted disruption of annexin II inhibits angiogenesis in vitro and tumor growth in vivo*. Proc. Am. Assoc. Cancer Research 43, A# 894, 2002.
43. Tarui, T., et al., *Plasmin-induced migration of endothelial cells. A potential target for the anti-angiogenic action of angiostatin*. J Biol Chem, 2002. 277(37): p. 33564-70.
44. Chiang, Y., et al., *Specific down-regulation of annexin II expression in human cells interferes with cell proliferation [In Process Citation]*. Mol Cell Biochem, 1999. 199(1-2): p. 139-47.
45. Vishwanatha, J.K., et al., *Enhanced expression of annexin II in human pancreatic carcinoma cells and primary pancreatic cancers*. Carcinogenesis, 1993. 14(12): p. 2575-9.